Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
[Biosimilar of interferon-beta 1b in the treatment of multiple sclerosis and the own experience in the use of ronbetal.]
Center for Drug Evaluation and Research Approval Letter, application number: 21-897
Characteristics of persons with overactive bladder of presumed neurologic origin: Results from the boston area community health (BACH) survey.
Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.
Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study.
FTY720, sphingosine 1-phosphate receptor modulator, selectively radioprotects hippocampal neural stem cells.
The genetic and environmental bases of complex human-disease: extending the utility of twin-studies.
Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases.
FDA Approves First Drug for Lou Gehrig's Disease
Retinal Axonal Loss Begins Early in the Course of Multiple Sclerosis and Is Similar between Progressive Phenotypes.
TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis.
IL-1 signal affects both protection and pathogenesis of virus-induced chronic CNS demyelinating disease.
Graves' disease after treatment with Alemtuzumab for multiple sclerosis.
The Impact of Social Media on Dissemination and Implementation of Clinical Practice Guidelines: A Longitudinal Observational Study.
In multiple sclerosis oligoclonal bands connect to peripheral B cell responses.
Multiple Sclerosis: Changes in Microarchitecture of White Matter Tracts after Training with a Video Game Balance Board.
Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification.
Rationale and design of a clinical trial investigating resistance training as an aid to smoking cessation in persons with multiple sclerosis.
Low-contrast multifocal visual evoked potentials: Identifying more shades of gray in MS.
Microglia: Architects of the Developing Nervous System.
Elevation of Ser9 phosphorylation of GSK3β is required for HERV-W env-mediated BDNF signaling in human U251 cells.
Ustekinumab approved for psoriatic arthritis in US, Europe
Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
Role of Proangiogenic Factors in Immunopathogenesis of Multiple Sclerosis.
Sex ratio of multiple sclerosis in persons born from 1930 to 1979 and its relation to latitude in Norway.
Pages
« first
‹ previous
…
159
160
161
162
163
164
165
166
167
…
next ›
last »